Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Integrins01:10

Integrins

4.8K
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
4.8K
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

3.3K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
3.3K
Activation of Integrins01:15

Activation of Integrins

4.3K
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
4.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PET Imaging of Accessible Prostate-Specific Membrane Antigen Reveals Dose-Dependent and Tumor Burden-Driven Variability.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Stability of the translocator protein 18 kDa density within cognitive circuits in brains of virally-suppressed people with HIV.

AIDS (London, England)·2026
Same author

Fluorine-18-labeled PET radiotracers for imaging the macrophage colony-stimulating factor 1 receptor (CSF1R).

EJNMMI radiopharmacy and chemistry·2026
Same author

PET radiotracer targeting the complement C3a receptor.

Nuclear medicine and biology·2025
Same author

Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1.

eLife·2025

Related Experiment Video

Updated: May 4, 2026

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

2.2K

Heterobivalent agents targeting PSMA and integrin-αvβ3.

Hassan M Shallal1, Il Minn, Sangeeta R Banerjee

  • 1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions , Baltimore, Maryland 21287, United States.

Bioconjugate Chemistry
|January 14, 2014
PubMed
Summary

This study introduces a novel heterobivalent (HtBv) imaging agent that simultaneously targets prostate-specific membrane antigen (PSMA) and integrin-αvβ3. This dual-targeting approach aims to overcome tumor heterogeneity for improved cancer imaging.

More Related Videos

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

6.2K
Modification and Functionalization of the Guanidine Group by Tailor-made Precursors
09:45

Modification and Functionalization of the Guanidine Group by Tailor-made Precursors

Published on: April 27, 2017

10.0K

Related Experiment Videos

Last Updated: May 4, 2026

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

2.2K
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

6.2K
Modification and Functionalization of the Guanidine Group by Tailor-made Precursors
09:45

Modification and Functionalization of the Guanidine Group by Tailor-made Precursors

Published on: April 27, 2017

10.0K

Area of Science:

  • Biomedical imaging
  • Cancer diagnostics
  • Molecular targeting

Background:

  • Differential surface protein expression between normal and malignant cells is key for targeted cancer therapies.
  • Tumor heterogeneity poses a challenge, as reliable tumor-specific markers are not always present.
  • Development of flexible targeting platforms is needed to address multiple markers concurrently.

Purpose of the Study:

  • To synthesize and evaluate a novel heterobivalent (HtBv) imaging agent.
  • To assess the agent's ability to target both prostate-specific membrane antigen (PSMA) and integrin-αvβ3.
  • To address tumor heterogeneity in cancer imaging through dual-targeting.

Main Methods:

  • Synthesis of heterobivalent (HtBv) agents functionalized with DOTA or IRDye800CW.
  • Biochemical and in vitro evaluation of binding affinities to PSMA and integrin-αvβ3.
  • Preliminary in vivo evaluation using xenografts overexpressing target markers.

Main Results:

  • DOTA-conjugated HtBv probe 9 exhibited binding affinities to PSMA and αvβ3 comparable to monovalent compounds.
  • Conformational analysis supported the model of probe 9 binding to both targets.
  • IRDye800-conjugated HtBv probe 10 demonstrated target-specific binding in xenografts.

Conclusions:

  • The developed heterobivalent (HtBv) agents show promise for dual-targeted imaging.
  • This approach may help overcome limitations posed by tumor heterogeneity in cancer imaging.
  • Potential for improved visualization of malignant cells and tissues.